Pacific Biosciences Of California (PACB) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.63% |
| Dec 31, 2025 | -27.66% |
| Sep 30, 2025 | -7.45% |
| Jun 30, 2025 | 14.41% |
| Mar 31, 2025 | -19.20% |
| Dec 31, 2024 | -67.10% |
| Sep 30, 2024 | -9.84% |
| Jun 30, 2024 | -8.36% |
| Mar 31, 2024 | -46.64% |
| Dec 31, 2023 | -43.89% |
| Sep 30, 2023 | -27.23% |
| Jun 30, 2023 | -67.21% |
| Mar 31, 2023 | -34.90% |
| Dec 31, 2022 | -65.15% |
| Sep 30, 2022 | -29.41% |
| Jun 30, 2022 | -54.36% |
| Mar 31, 2022 | -76.60% |
| Dec 31, 2021 | -70.74% |
| Jun 30, 2021 | -35.04% |
| Mar 31, 2021 | -59.10% |
| Dec 31, 2020 | -0.04% |
| Sep 30, 2020 | -28.77% |
| Jun 30, 2020 | -10.54% |
| Mar 31, 2020 | -12.49% |
| Dec 31, 2019 | 21.65% |
| Sep 30, 2019 | 13.10% |
| Jun 30, 2019 | 8.64% |
| Mar 31, 2019 | 6.94% |
| Dec 31, 2018 | 1.88% |
| Sep 30, 2018 | 1.83% |
| Jun 30, 2018 | 9.91% |
| Mar 31, 2018 | -8.37% |
| Dec 31, 2017 | 8.97% |
| Sep 30, 2017 | 3.82% |
| Jun 30, 2017 | -3.12% |
| Mar 31, 2017 | 19.06% |
| Dec 31, 2016 | 16.51% |
| Sep 30, 2016 | 21.37% |
| Jun 30, 2016 | 15.87% |
| Mar 31, 2016 | -1.58% |
| Dec 31, 2015 | 24.19% |
| Sep 30, 2015 | 1.24% |
| Jun 30, 2015 | 4.22% |